Answers are grounded in this paper and cite their sources.
Summary: According to a new NIA AA proposal, decreased cerebrospinal fluid (CSF) levels of beta-amyloid (1–42) (Aβ42) reflect pathological changes in Alzheimer’s disease, whereas patients with only an increase of tau do not have Alzheimer’s pathology. We first compared this classification with one based on the ratio between phospho-tau/Aβ42 and then with one based on neuropsychological test results (CERAD-NAB Subtests, Digit Span forward and backward, language comprehension, pictures recognition test, Beck’s Depression Inventory). Irrespective of the cross-tabulation approach, the NIA AA criteria led to a drop of about 40 % to 50 % of AD patients compared to the phospho-tau/Aβ42 ratio. Neuropsychological scores correctly predicted 89.1 % of CSF negative patients, 73.3 % of Aβ42 positive patients, but only a small number of the phospho-tau positive patients. We argue that neuropsychological assessment still plays a crucial role in the assessment of Alzheimer’s dementia.
No takes yet. Share an insight, caveat, or question.
Hildebrandt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: